Menu Back toWhat Do We Do Now? Why You Need A Resource for Ethical Questions During Drug Development

DIA 2021 Global Annual Meeting


What Do We Do Now? Why You Need A Resource for Ethical Questions During Drug Development

Session Chair(s)

Karla  Childers, MS

Karla Childers, MS

  • Bioethics & Strategic Projects Leader, Office of the Chief Medical Officer
  • Johnson & Johnson, United States
Complex ethical questions are inherent in drug development. Teams need resources to provide independent, thoughtful and informed assistance with these questions. We will look at models of ethical consultation that match organizational needs.
Learning Objective : Recognize situations in which ethical consultation may be appropriate, useful and necessary; Identify potential resources to provide ethical consultation appropriate to the needs of the development program; Describe how to obtain ethical consultation in advance of situations in which it may be necessary.

Speaker(s)

Lindsay  McNair, MD, MPH, MS

Models for Bioethical Consultation to Drug Development Teams

Lindsay McNair, MD, MPH, MS

  • Chief Medical Officer
  • WCG, United States